T-type calcium channel blockers: a patent review (2012–2018)

References

• Nowycky MC, Fox AP, Tsien RW. Three types of neural calcium channel with different calcium agonist sensitivity. Nature. 1985 Aug;316:440–443.
   PubMed Web of Science ®Google Scholar
• Perez-Reyes E, Cribbs LL, Daud A, et al. Molecular characterization of a neuronal low-voltage-activated T-type calcium channel. Nature. 1998 Feb;391:896.
   PubMed Web of Science ®Google Scholar
• Errel EA, Campbell KP, Harpold MM, et al. Nomenclature of voltage-gated calcium channels. Neuron. 2000 Mar;25:533–535.
   PubMed Web of Science ®Google Scholar
• Talley EM, Cribbs LL, Lee JH, et al. Differential distribution of three members of a gene familily encoding low voltage-activated (T-Type) calcium channels. J Neurosci. 1999 Mar;19(6):1895–1911.
   PubMed Web of Science ®Google Scholar
• Trimmer JS, Rhodes KJ. Localization of voltage gated ion channels in mammalian brain. Annu Rev Physiol. 2004 Mar;66:477–519.
   PubMed Web of Science ®Google Scholar
• Molineux ML, McRory JE, McKay BE, et al. Specific T-type calcium channel isoforms are associated with distinct burst phenotypes in deep cerebellar neuron. Proc Natl Acad Sci U S A. 2006 Apr;103(14):5555–5560.
   PubMed Web of Science ®Google Scholar
• Fry CH, Wu C, Wu C. T-type calcium channels in non-vascular smooth muscles. Cell Calcium. 2006 Aug;40(2):231–239.
   PubMed Web of Science ®Google Scholar
• Vassort G, Talavera K, Alvarez JL. Role of T-type Ca2+ channels in the heart. Cell Calcium. 2006 Aug;40(2):205–220.
   PubMed Web of Science ®Google Scholar
• Shin JB, Lewin GR, Heppenstall PA, et al. A T-type calcium channel required for normal function of a mammalian mechanoreceptor. Nat Neurosci. 2003 Jul;6(7):724–730.
   PubMed Web of Science ®Google Scholar
• Devergnas A, Chen E, Ma Y, et al. Anatomical localization ofCav3.1 calcium channels and electrophysiological effects of T-type calcium channel blockade in the motor thalamus of MPTP-treated monkeys. J Neurophysiol. 2016 Jan;115:470−485.
   PubMed Web of Science ®Google Scholar
• Contreas D. The role of T-channels in the generation of thalamocotical rhythms. CNS Neurol Disord Drug Targets. 2006 Dec;5(6):571–585.
   PubMed Web of Science ®Google Scholar
• Iftinca MC, Zamponi GW. Regulation of neuronal T-type calcium channels. Trends Pharmacol Sci. 2009 Jan;30(1):32–40.
   PubMed Web of Science ®Google Scholar
• Shen FY, Chen ZY, Wang YW, et al. Alleviation of neuropathic pain by regulating T-type calcium channels in rat anterior cingulate cortex. Mol Pain. 2015 Mar;11(7):11–17.
   PubMedGoogle Scholar
• Bourinet E, Laffray S, Francois, A. T-type calcium channels in neuropathic pain. Pain. 2016 Feb;157(suppl):S15–22.
   PubMedGoogle Scholar
• Snutch TP, David LS. T-type calcium channels: an emerging therapeutic target for the treatment of pain. Drug Dev Res. 2006 May;67:405–415.
   Web of Science ®Google Scholar
• Giordanetto P, Willberg A, Knerr, L. T-type calcium channels inhibitors: a Patent Review. Expert Opin Ther Patents. 2011 Nov;21(1):85–101.
   PubMed Web of Science ®Google Scholar
• Kabushikikaisha ZK. Use of Cav3.1 selective T-type calcium channel antagonists. WO2012094615 A2. 2012.
   Google Scholar
• Kyowa Hakko Kirin Co Ltd. Ring-fused heterocyclic derivatives. US9000186 B2. 2015.
   Google Scholar
• Purdue Pharma IP. Fused and spirocycle compounds and use of thereof. US8883816. 2014.
   Google Scholar
• Vertex Pharmaceutical Inc. Ion channel modulators and methods of use. US8546414. 2013
   Google Scholar
• Vater W, Kroneberg G, Hoffmeister F, et al. Pharmacology of 4-(2ʹ-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (Nifedipine, BAY a 1040). Arzneim-Forsch. 1972 Jan;22(1):1–14.
   PubMedGoogle Scholar
• Arrowsmith JE, Campbell SF, Cross PE, et al. Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents. J Med Chem. 1986 Sep;29(9):1696–1702.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Nardi D, Pennini R, et al. Asymmetric N-(3,3-diphenylpropyl)aminoalkyl esters of 4-aryl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acids with antihypertensive activity. Eur J Med Chem. 1998 Jun;33(5):399–420.
   Web of Science ®Google Scholar
• E.R. Squibb & sons, Inc. Use of calcium channel blocker for preventing or treating anxiety. EP0400665 A2. 1990
   Google Scholar
• Teleb M, Zamponi GW, Fahmy H, et al. Synthesis of new N3-substituted dihydropyrimidine derivatives as L-/T-type calcium channel blockers. Eur J Med Chem. 2017 Jul;134(7):52–61.
   PubMedGoogle Scholar
• Taleb M, Zamponi GW, Fahmy H, et al. Synthesis and biological evaluation of novel N3-subatituted dihydropyrimidine derivatives as T-type calcium blockers and their efficacy as analgesics in mouth model of inflammatory pain. Bioorg Med Chem. 2017 Mar;25(6):1926–1938.
   PubMed Web of Science ®Google Scholar
• Xuanzhu Pharma Co., Ltd 1,4-Dihydropyridine-3,5-dicarboxylate derivatives and preparation and use thereof. US9198902 B2. 2015.
   Google Scholar
• Nissan Chemical Industry Ltd. T-type calcium channel inhibitor. US2016/0237071 A1. 2016.
   Google Scholar
• Nissan Chemical Industry Ltd. Triazinone compound and T-type calcium channel inhibitor. US9403798B2;2016.: JP 6304492 B2 IL234874 A. 2018.
   Google Scholar
• Nissan Chemical Industry Ltd. Substituted triazinone compound and T-type calcium channel inhibitor. US 0340322 A1. 2016.
   Google Scholar
• Kinki University, Osaka, Fuso pharmaceutical Industries, Ltd. T-type calcium channel inhibitor. US 0065947 A1. 2018.
   Google Scholar
• Nguyen HD, Okada T, Toyooka N, et al. Design and synthesis of novel anti-hyperalgesic agents based on 6-prenylnaringenin at the T-type calcium channel blockers. Bioorg Med Chem. Forthcoming 2018 Jul on line.
   Web of Science ®Google Scholar
• Concert Pharmaceuticals. Inc. Deuterated tetrahydronaphthalene derivatives. EP3144296 A1. 2017.
   Google Scholar
• Korea Institute of Science & Technology (KIST). Isoprenyl-croman-3-ol compounds. KR10-1679262. 2016.
   Google Scholar
• UTI Limited Partnership, University of Montana. T-type calcium channel modulator and uses thereof. US 0233374 A1. 2017.
   Google Scholar
• Yang G, Barrow JC, Shipe WD, et al. Discovery of 1,4-substituted piperidines as a potent and selective inhibition of T-type calcium channels. J Med Chem. 2008 Oct;51(20):6471–6477.
   PubMed Web of Science ®Google Scholar
• Gadotti VM, You H, Zamponi GW, et al. Analgesic effect of a mixed T-type channel inhibitor/CB2 receptor agonist. Mol Pain. 2013Jul;9:32.
   PubMed Web of Science ®Google Scholar
• You H, Gadotti VM, Diaz P, et al. Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands. Mol Pain. 2011 Nov;7:89–101.
   PubMed Web of Science ®Google Scholar
• Balden C, Diaz P, Zamponi GW, et al. Characterization of novel cannabinoid based T-type calcium channel blocker with analgesic effects. ACS Chem Neurosci. 2015 Feb;6(2):277–287.
   PubMed Web of Science ®Google Scholar
• Neuromed Pharmaceuticals Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers. WO2009/246540 A1. 2009.
   Google Scholar
• Taro Pharmaceuticals Inc. N-piperidinyl acetamide derivatives as calcium channel blockers. EP2 300 007 B1. 2018.
   Google Scholar
• Afasci. Inc. Ion channel inhibitory compounds, Pharmaceutical formulations and uses. WO2017083867 A1. 2017.
   Google Scholar
• Merck sharp & Dohme Corp. Imidazolyl methyl piperidine T-type calcium channel antagonists. US 9051299 B2. 2015.
   Google Scholar
• Zalicus Pharmaceuticals Ltd. Selective calcium channel modulators. US 0220564 A1. 2012.
   Google Scholar
• Korea institutes of Science and Technology (KIST). Pyrazolyl piperidine derivatives as T-type calcium blockers. KR10-1306271 B1. 2013.
   Google Scholar
• Korea institutes of Science and Technology (KIST). Phenylpyrazolyl methyl-2-(4-substituted piperidynyl)acetamide derivatives as calcium blockers. KR10-1293669 B1. 2013.
   Google Scholar
• Doddareddy MR, Choo H, Pae AN, et al. 3D pharmacophore base virtual screening of T-type calcium channel blockers. Bioorg Med Chem. 2007 Jan;15(2):1091–1105.
   Google Scholar
• Lee JH, Nam G, Keum G, et al. Synthesis and biological evaluation of 1-(iso-oxazol-5-ylmethylaminoethyl)-4-phenylpyridine and piperidine derivatives as potent T-type calcium channel blocker with anti-nociceptive effect in a neuropathic pain model. Eur J Med Chem. 2014 Mar;74(3):246–257.
   PubMedGoogle Scholar
• Korea institutes of Science and Technology (KIST). 5-(Substituted aminoalkyl)isoxazole derivatives as T-type calcium channel blockers. KR10-1389374 B1. 2014.
   Google Scholar
• Korea institutes of Science and Technology (KIST). Phenoxypropanol derivatives and pharmaceutical composition including the same. US 9459120 B2 2016. WO 2013081420 A2. 2013.
   Google Scholar
• Korea institutes of Science and Technology (KIST). A new 1-(4-halophenyloxo- or thio)-3-(4-substitutedpiperazin-yl)propan-2-ol as T-type calcium channel blocker and pharmaceutical thereof. KR 20120066699 A1. 2012.
   Google Scholar
• Park JE, Rho EJ, Jang JW, et al. Synthesis and biological evaluation of 1-(2-hydroxy-3-phenyloxy-propyl)piperazine derivatives as T-type calcium channel blockers. Booorg Med Chem Lett. 2013 Mar;23(6):1887–1890.
   PubMed Web of Science ®Google Scholar
• Korea institutes of Science and Technology (KIST). Novel 5-membered heteroaromatic ring compounds having activity for T-type calcium channel. KR 20120088398 A1. 2012.
   Google Scholar
• Korea institutes of Science and Technology (KIST). 1,4-Diazepane pyrazole derivatives as T-type calcium blockers. KR 10-1247690. 2013.
   Google Scholar
• Kim JH, Nam G. Synthesis and evaluation of 6-pyrazoylamido-3N-substituted azabicyclo[3,1,0]hexane derivatives as T-type calcium channel inhibitors for treatment of neuropathic pain. Bioorg Med Chem. 2016 Nov;24(21):5028–5035.
   PubMed Web of Science ®Google Scholar
• Korea institutes of Science and Technology (KIST). 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane compounds as calcium channel inhibitors. US 8895602 B1. 2014.
   Google Scholar
• AbbVie Inc. Substituted pyrrolo[1,2-a]pyrazines as calcium channel blockers. US 8101614 B2. 2010.
   Google Scholar
• AbbVie Inc. Methods of treating diabetic neurophathy using benzensulfonamides. US 2013-0178477 A1. 2013.
   Google Scholar
• Zhang Q, Xia Z, Jarvis MF, et al. Optimization of ADME properties for sulfonamides leading to the discovery of T-type calcium channel blocker, ABT-639. ACS Med Chem Lett. 2015 Apr;6(6):641–644.
   PubMed Web of Science ®Google Scholar
• AbbVie Inc. Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers. US 8669255 B2. 2014.
   Google Scholar
• Hong JR, Nam G, Choi Y.J. Synthesis and diabetic neuropathic pain-alleviation effects of 2N-(pyrazol-3yl)methylbenzo[d]isothiazole-1,1,-dioxide derivatives. Bioorg Med Chem. 2017 Sep;25(17):4677–4685.
   PubMed Web of Science ®Google Scholar
• Korea institutes of Science and Technology (KIST). Compounds capable of inhibiting voltage gated calcium ion channel, and pharmaceutical compounds comprising the same. US 9493423 B2. 2016.
   Google Scholar
• Kim JH, Nam G, Chung H, et al. Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment. Eur J Med Chem. 2016 Nov;123:665–672.
   PubMed Web of Science ®Google Scholar
• Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers. US 2014/0113898 A1. 2014.
   Google Scholar
• Merck Sharp & Dohme Corp. Heterocycle phenyl amide T-type calcium channel agonists. US 8637513 B2. 2014.
   Google Scholar
• Merck Sharp & Dohme Corp. Heterocycle phenyl amide T-type calcium channel agonists. US 8987310 B2. 2015.
   Google Scholar
• Actelion pharmaceuticals Ltd. Triazole compounds as T-type calcium channel blockers. WO 2016/041892 A1 2016. PCT/EP 2015/070934. 2015.
   Google Scholar
• Idorsia phamaceuticals Ltd. Pyrazole compounds and their use as T-type calcium channel blockers. US 2018/0105496 A1. 2018.
   Google Scholar
• Bezenç O, Heidmann B, Fournier E, et al. Discovery of a potent, selective T-type calcium channel blocker as a drug candidate for the treatment of generalized epilepsies. J Med Chem. 2017 Dec;60(23):9769–9789.
   PubMed Web of Science ®Google Scholar
• RaQualia Pharma. Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers. US 9101616 B2. 2015.
   Google Scholar
• University of Virginia. T-type calcium channel inhibitors. US 2016/0136115 A1. 2016.
   Google Scholar
• Toa Eiyo Ltd. Fused imidazole derivatives. CN 102906074 A. 2013.
   Google Scholar
• Xie X, Van Deusen AL, Barrett PQ, et al. Validation of high throughput screening assays against three subtypes of Ca(v)3 T-type channels using molecular and pharmacologic approaches. Assay Drug Dev Technol. 2007 Apr;5(2):191–203.
   PubMed Web of Science ®Google Scholar
• Zamponi GW. Targeting voltage gated calcium channels in neurological and psychiatric diseases. Nat Rev Drug Discovery. 2016 Jan;15(1):19–34.
   PubMed Web of Science ®Google Scholar
• Miwa H, Kondo T. T-type calcium channel as a new therapeutic target for tremor. Cerebellum. 2011 Sep;10(3):563–569.
   PubMed Web of Science ®Google Scholar
• Miwa H, Kondo T, Kajimoto Y, et al. Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats. Pharmacol Biochem Behave. 2011 Feb;97(4):656–659.
   PubMed Web of Science ®Google Scholar
• Galven A, Devergnas A, Wichmann T, et al. Lack of antiparkinsonian Effects of systemic injections of the specific T-type calcium channel blocker ML218 in MPTP-treated monkeys. ACS Chem Neurosci. 2016 Nov;7(11):1543–1551.
   PubMed Web of Science ®Google Scholar
• Kerckhove N, Pereira B, Eschalier A, et al. Efficacy and safety of a T-type calcium channel blocker in patients with neuropathic pain: a proof-of-concept, randomized, blind and controlled trial. Eur J Pain. 2018 Aug;22(7):1321–1330.
   PubMed Web of Science ®Google Scholar
• Wallace M, Duran R, Nothaft W, et al. A randomized, double blind, placebo-controlled crossover study of the T-type calcium channel blocker ABT-639 in an intradermal capsaicin experimental pain model in healthy adults. Pain Med. 2016 Mar;17(3):551–560.
   PubMed Web of Science ®Google Scholar
• Egan MF, Zhao X, Michelson D, et al. Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia. Hum Psychopharmacol. 2013 Mar;28(2):124–133.
   PubMed Web of Science ®Google Scholar
• Naples JG. Calcium-channel blockers as therapeutic agents for acquired sensorineural hearing loss. Med Hyphothses. 2017 Jul;104:121–5. 69.
   PubMed Web of Science ®Google Scholar
• Sang L, Zheng T, Zheng Q, et al. Otoprotective effects of ethosuximide in NOD/LtJ mice with age-related hearing loss. Int J Mol Med. 2017 Jul;40(1):146–154.
   PubMed Web of Science ®Google Scholar
• Yu YF, Wu WY, Pan C, et al. Protection of the cochlear hair cells in adults C52BL/6J mice by T-type calcium channel blockers. Exp Ther Med. 2016 Mar;11(3):1039–1044.
   PubMed Web of Science ®Google Scholar